Therakind is looking for additional partners to market Jylamvo® in US, China, Japan, parts of the EU, and ROW.
Jylamvo is an EMA authorised oral liquid methotrexate, a cytotoxic oncological / immunosuppressant product.
The product was granted a European Marketing Authorisation by the European Medicines Agency (EMA) on 29 March 2017.
Jylamvo is authorised in the EU for use in the following indications:
In rheumatological and dermatological diseases
Active rheumatoid arthritis in adult patients.
Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non‑steroidal anti‑inflammatory drugs (NSAIDs) has been inadequate.
Severe, treatment‑refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.
Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over
To register interest in Jylamvo® or to discuss partnering/ licencing opportunities please contact email@example.com